Insider · CIK 0002071589
Rachel Yap Martens
Files at LXRX (LEXICON PHARMACEUTICALS, INC.). First filing -, latest -.
In brief
Rachel Yap Martens files SEC Form 4 as officer at LXRX (LEXICON PHARMACEUTICALS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Rachel Yap Martens has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +67,090 | - | - | 67,090 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | FTax withholding Common Stock | -35,826 | $1.47 | $53k | 31,264 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -67,090 | - | - | 134,180 | Mar 3, 2026 |
| Feb 12, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitsderivative | +193,740 | $0.00 | $0 | 193,740 | Feb 17, 2026 |
| Feb 12, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +290,620 | $0.00 | $0 | 290,620 | Feb 17, 2026 |
Questions about Rachel Yap Martens
Answered from the filings on this page, as of the latest one.
Is Rachel Yap Martens buying or selling?
Rachel Yap Martens has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Rachel Yap Martens's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Rachel Yap Martens has 0.
Where does Rachel Yap Martens file Form 4?
Rachel Yap Martens has filed Form 4 at LXRX (LEXICON PHARMACEUTICALS, INC.) as SVP, Partnerships & Corp Strat. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.